Novabridge Biosciences ADR (NBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 0 | 632 | -32,124 | 13,813 | 236,424 |
| Cost of Goods | N/A | N/A | 3,949 | 7,286 | N/A |
| Gross Profit | N/A | 632 | -36,073 | 6,527 | 236,424 |
| Operating Expenses | 51,426 | 72,649 | 250,422 | 331,847 | 212,582 |
| Operating Income | -51,426 | -72,017 | -285,546 | -325,034 | 23,842 |
| Interest Expense | 0 | 0 | 1 | 0 | 147 |
| Other Income | 1,730 | -10,200 | -77,878 | -41,331 | 50,349 |
| Pre-tax Income | -49,696 | -82,217 | -363,425 | -366,365 | 74,044 |
| Income Tax | N/A | N/A | 101 | -495 | 1,874 |
| Net Income Continuous | -49,696 | -82,217 | -363,526 | -365,870 | 72,170 |
| Net Income Discontinuous | 27,466 | -125,512 | N/A | N/A | N/A |
| Net Income | $-22,230 | $-207,729 | $-363,526 | $-365,870 | $72,170 |
| EPS Basic Total Ops | -0.27 | -2.50 | -4.41 | -4.82 | 1.24 |
| EPS Basic Continuous Ops | -0.61 | -0.99 | -4.41 | -4.82 | 1.24 |
| EPS Basic Discontinuous Ops | 0.34 | -1.51 | N/A | N/A | N/A |
| EPS Diluted Total Ops | -0.27 | -2.50 | -4.41 | -4.82 | 1.06 |
| EPS Diluted Continuous Ops | -0.61 | -0.99 | -4.41 | -4.82 | 1.06 |
| EPS Diluted Discontinuous Ops | 0.34 | -1.51 | N/A | N/A | N/A |
| EPS Diluted Before Non-Recurring Items | -0.61 | -2.07 | -4.24 | -4.82 | 1.06 |
| EBITDA(a) | $-50,448 | $-70,956 | $-276,293 | $-319,677 | $27,387 |